• News by Topic

  • News by Topic

  • Relationships news

  • Mind and body

    "Live as if your were to die tomorrow. Learn as if you were to live forever. You must learn to be still in the midst of activity and be vibrantly alive in repose."

    --Gandhi

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.

Vote!

Long-Acting Injectable Risperidone Leads to Greater Adherence, Relapse Prevention in Patients With Schizophrenia

Patients with a recent first episode of schizophrenia who are treated with a long-acting injectable (LAI) formulation of the antipsychotic risperidone may experience lower rates of psychotic relapse and better control of psychotic symptoms than those treated with oral risperidone, according to a study published this week in JAMA Psychiatry.For the study, Kenneth Subotnik, Ph.D., a research psychologist at the University of California, Los Angeles, and colleagues randomized 83 patients with recent-onset schizophrenia to receive LAI risperidone (25 mg every two weeks) or oral risperidone (2 mg daily) over a...

read more...

Share |

Published By: Psychiatric News - Monday, 29 June, 2015

Copyright © 2016 Psychology One. All rights reserved. This site is for education & information purposes. This site is not a substitute for professional psychological, medical or psychiatric treatment.